Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026

On November 4, 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, reported the online publication of abstracts submitted to the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract 4498 – Oral Presentation
Title: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): A deepening of measurable residual disease (MRD) response and recovery from cytopenias
Session name: Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL
Presentation date and time: December 12, 2026; 5:00 – 5:15 PM ET
Presentation room: MCCNO – 265-268
Publication number: 377
Presenting author: Elias Jabbour, MD; D.B. Lane Cancer Research Fund Distinguished Professor in Leukemia Research; Section Chief Acute Lymphoblastic Leukemia; MD Anderson Cancer Center, Houston, Texas

Summary: In an evaluation of efficacy, safety and hematologic recovery during the first three months after infusion to define early clinical expectations following obe-cel treatment, MRD responses continued to deepen beyond month one, with patients who achieved delayed MRD negativity experiencing outcomes comparable to early responders. These findings may help define early clinical expectations following obe-cel treatment and inform patient management strategies.

Abstract 273 – Poster Presentation
Title: Analytical and clinical concordance of droplet digital PCR (ddPCR) and quantitative PCR (qPCR) assays to monitor obecabtagene-autoleucel (obe-cel) presence in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
Session Name: 614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III
Presentation date and time: December 14, 2026; 6:00 PM – 8:00 PM ET
Presentation room: MCCNO – Hall F
Publication number: 5094
Presenting author: Aaron Logan, MD; Professor of Medicine; Director, Cellular Therapy Program; Division of Hematology, Blood and Marrow Transplant, and Cellular Therapy; University of California, San Francisco (UCSF), San Francisco, California

Summary: Recently, a novel qPCR assay was developed, validated, and made available in a reference laboratory to enable monitoring of obe-cel levels. Concordance between the ddPCR and qPCR assay results within this subset of patients from FELIX is sufficient and acceptable to support the use of the commercially available qPCR assay for patients in clinical practice.

Abstract 11291 – Poster Presentation
Title: Initial results of the phase 1 UKMRA ALARIC trial assessing BCMA and BCMA/CD19 CAR-T for the treatment of relapsed/refractory AL amyloidosis
Session name: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Presentation date and time: December 12, 2026, 5:30-7:30 PM
Presentation room: MCCNO – Hall F
Publication number: 2185
Presenting author: Lydia Lee, Associate Professor, UCL Cancer Institute; Consultant Haematologist, UCLH

Summary: ALARIC is a phase 1 trial evaluating Fab-based BCMA (D8) CAR-T cells, alone or co-transduced with a CD19 CAR (AUTO8), in relapsed/refractory systemic AL amyloidosis. All of the first four patients treated with D8 alone achieved rapid complete haematological response, with good tolerability and encouraging improvements in organ function at a median five-month follow-up.

(Press release, Autolus, NOV 4, 2026, View Source [SID1234674210])

Personalis Reports Third Quarter Results

On November 4, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported financial and operational results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recent Strategic and Operational Highlights

Launched NeXT Personal Real-Time Variant Tracker: Commercially launched optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report, which identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing.
Reported pre-interim results from prospective Triple Negative Breast Cancer (TNBC) B-STRONGER-1 study: Personalis’ study is a multi-site, prospective study evaluating ctDNA dynamics in stage I-III TNBC patients receiving neoadjuvant therapy (NAT). Results showed high sensitivity, achieving a 96% ctDNA detection rate at baseline with 83.3% of positive detections at T1 in the ultrasensitive range below 100 PPM. Also, the results showed an 82% ctDNA clearance rate following two cycles of NAT.
Demonstrated the value of ultrasensitive ctDNA for predicting early immunotherapy response: A study conducted with The University of California, San Diego (UCSD) for 55 patients across 8 metastatic cancer types showed that an ultrasensitive assay may provide resolution in cases of heterogeneous response to stratify patients with radiographically stable disease into distinct risk groups, and dynamic ctDNA monitoring during immunotherapy provides lead time for identifying patients at high risk of progression.
Third Quarter 2026 Financial Results Compared with Third Quarter 2025

Quarterly Revenue: Total revenue of $25.6 million compared with $14.5 million, primarily driven by growth in clinical test revenue, as well as core revenue from increased population sequencing and higher pharma testing services.
Clinical Revenue: Clinical test revenue of $4.4 million compared with $0.4 million, resulting from the increase in test volume and also a full quarter of Medicare covered IO test volume, in addition to revenue from breast and lung cancer covered tests; delivered 13,157 clinical tests compared with 4,388.
Core Revenue Streams: Revenue from pharma testing services and all other customers totaled $17.2 million compared with $13.2 million. Revenue from population sequencing (the VA MVP) totaled $4.0 million compared with $0.2 million.
Cash Position: Ended the quarter with approximately $190.6 million in cash, cash equivalents, and short-term investments.
CEO Commentary

"These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care," said Chris Hall, Chief Executive Officer of Personalis. "Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners."

Full Year 2026 Outlook

As a result of the announcement on July 20, 2026, that Personalis and Tempus AI, Inc. have entered into an Agreement and Plan of Merger, Personalis will no longer provide financial guidance or conduct a quarterly earnings conference call.

(Press release, Personalis, NOV 4, 2026, View Source [SID1234674226])

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

On November 4, 2026 CRISPR Therapeutics (Nasdaq: CRSP) reported that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place December 12 to 15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Zugocabtagene geleucel (zugo-cel), an off-the-shelf CRISPR-Cas9 engineered CD19 CAR T cell therapy demonstrates dose-dependent efficacy in highly refractory large B-cell lymphoma
Abstract Number: 706
Session Type: Oral Presentation
Session Title: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond
Session Date and Time: Sunday, December 13, 2026, 5:15 p.m. CST

A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About Zugocabtagene Geleucel (zugo-cel; formerly CTX112)
Zugo-cel is a wholly-owned, allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate targeting Cluster of Differentiation 19 (CD19), in development for both autoimmune and immuno-oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9 for targeted gene knockout and CAR insertion, enabling immune evasion and enhanced T effector cell potency, and is administered following a standard lymphodepletion regimen without the need for human leukocyte antigen (HLA) matching. In autoimmune disease, zugo-cel is being investigated in three ongoing basket trials. The rheumatology basket trial is enrolling adult patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM). The hematology basket trial is enrolling patients with immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). The neuroimmune basket trial is enrolling patients with progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated Disease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). In immuno-oncology, zugo-cel is being investigated in a trial in adult patients with relapsed or refractory B-cell malignancies.

(Press release, CRISPR Therapeutics, NOV 4, 2026, View Source [SID1234674241])

ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program

On November 4, 2026 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), reported new and updated data from the ZYNLONTA (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Across the presentations, the data provide additional insight into the depth and durability of response observed with ZYNLONTA across multiple B-cell lymphomas and treatment settings, including in difficult-to-treat patient populations. Oral presentations include expanded LOTIS-7 data evaluating ZYNLONTA in combination with glofitamab (COLUMVI) in r/r DLBCL and updated data evaluating ZYNLONTA in r/r marginal zone lymphoma (MZL), as well as full results from the Phase 3 LOTIS-5 r/r DLBCL study and data from investigator-initiated trials in r/r mantle cell lymphoma (MCL) and r/r Waldenström macroglobulinemia (WM).

"We are pleased by the breadth of the ZYNLONTA clinical program and the growing body of evidence showcased through multiple presentations at ASH (Free ASH Whitepaper)," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "We are particularly encouraged by the strength of the updated LOTIS-7 data and the marginal zone lymphoma IIT data, which are both highly differentiated and continue to show deep and durable efficacy with manageable safety."

"We believe the emerging data from LOTIS-7 and MZL reinforce the best-in-class potential of ZYNLONTA in these settings and support our pursuit of an expanded role in treating these B-cell malignancies through potential compendia and regulatory pathways," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "ASH provides an important opportunity to engage with the hematology community on these findings and discuss plans to advance the clinical program, including planned Phase 3 studies. Through ZYNLONTA, we remain focused on delivering meaningful outcomes for patients in need while driving long-term value for our shareholders."

Select Oral Presentations: Clinical Highlights

LOTIS-7 Phase 1b study: ZYNLONTA plus glofitamab in relapsed or refractory LBCL Updated results from LOTIS-7 continue to demonstrate encouraging efficacy and safety findings with ZYNLONTA plus glofitamab, including in difficult-to-treat patient populations.

As of the June 15, 2026 data cutoff, at the ZYNLONTA 150 µg/kg starting dose + glofitamab:

· Among 97 efficacy-evaluable patients, the overall response rate (ORR) was 88.7%, and the complete response rate (CRR) was 75.3%.
· Patients had received a median of one prior treatment (range 1-5); 52.4% were primary refractory
· In patients with primary refractory disease, ORR was 78.4% and CRR was 64.7%. Among patients previously treated with prior CAR-T therapy, ORR was 74.1% and CRR was 63.0%.
· At a median follow-up of 10.35 months, median duration of response, duration of complete response and progression-free survival (PFS) had not been reached. The 12-month duration of complete response rate was 79.0%.
· In an exploratory MRD analysis of 12 patients who achieved a complete response, 50% achieved undetectable MRD as early as Cycle 2, Day 1, and 11 had undetectable MRD at end of treatment.
· Cytokine release syndrome (CRS) occurred in 32% of treated patients, predominantly Grade 1 (25.2%) or 2 (5.8%). One Grade 3 CRS event was reported, and no Grade 3 or higher ICANS events occurred. Three Grade 5 treatment-emergent adverse events were reported.

Authors conclude that the efficacy and safety findings support further investigation of ZYNLONTA plus glofitamab in a Phase 3 study.

Phase 2 IIT: Fixed-duration ZYNLONTA in relapsed or refractory marginal zone lymphoma

An investigator-led, multicenter Phase 2 study demonstrated high response rates and encouraging durability with fixed-duration ZYNLONTA in patients with relapsed or refractory MZL.

As of the July 1, 2026 data cutoff:

· Among 43 efficacy-evaluable patients, ORR was 93% and CRR was 74.4%.

· Patients had received a median of two prior treatments; 37% had primary refractory disease and 42% had experienced disease progression within 24 months of initial therapy.
· At a median follow-up of 23.2 months, the two-year PFS rate was 90.8%.
· The duration of response rate at 24 months was 90.9%.
· Among 46 treated patients, adverse events (AEs) were predominantly Grade 1–2. Grade 3 AEs (36 events) were reported in 23 patients (50%), and Grade 4 AEs (5 events) in five patients (10.9%). The most common Grade 3 events included anemia (n=5), lung infections (n=5), elevated ALT (n=4), alkaline phosphatase (n=3) and AST (n=1). Grade 4 events included neutropenia (n=2), thrombocytopenia (n=2) and hyponatremia (n=1). Four patients required dose reductions.

Authors conclude that ZYNLONTA demonstrated clinically meaningful activity with robust and durable complete responses in relapsed or refractory MZL, characterizing the responses as comparable with those reported for recently approved CAR-T therapy.

Phase 3 LOTIS-5 study: ZYNLONTA plus rituximab versus R-GemOx in relapsed or refractory DLBCL

Full results from the randomized Phase 3 LOTIS-5 study of 420 patients demonstrated a statistically significant improvement in the primary endpoint of PFS with ZYNLONTA plus rituximab compared with R-GemOx.

As of the data cutoff of February 16, 2026:

· Median PFS by independent review was 6.14 months with ZYNLONTA plus rituximab versus 4.73 months with R-GemOx (HR 0.73; 95% CI, 0.57–0.92; P=0.0083).
· ORR was 58.1% versus 45.2%, and CRR was 39.5% versus 26.7%, respectively.
· Median duration of complete response was 16.82 months versus 12.25 months. At 24 months, 48.5% versus 16.7% of patients who achieved a complete response remained in complete response.
· No statistically significant difference in overall survival was observed between treatment arms.
· Within the protocol-defined 105-day treatment-emergent adverse event reporting window, Grade 3 or higher events occurred in 74.0% versus 76.1% of patients, and Grade 5 events occurred in 13.2% versus 4.6%, respectively. Using a standard 30-day post-treatment window, Grade 5 events occurred in 1.5% versus 3.0%, respectively.

Authors conclude these findings establish ZYNLONTA plus rituximab as a standard treatment option in the second-line or later setting.

Presentation Details

Oral presentation details are as follows:

Abstract # Title Presentation Details Presenter
#238
Loncastuximab Tesirine Consolidation After Short-Course R-BAC Induction in BTKi-Exposed R/R Mantle Cell Lymphoma: Primary Endpoint Analysis from the Phase II Column Trial from Fondazione Italiana Linfomi (FIL)

Saturday, December 12, 2026

2:45 PM – 3:00 PM CT

Location: New Orleans Theatre A

Rita Tavarozzi, MD, University of Eastern Piedmont, Alessandria, Italy and SCDU of Hematology, IRCCS SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
#619
Updated Results from LOTIS-7: A Phase 1b Study Evaluating the Safety and Efficacy of Loncastuximab Tesirine in Combination with Glofitamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Sunday, December 13, 2026

12:00 – 12:15 p.m. CT

Location: New Orleans Theatre B

Juan P. Alderuccio, MD, Clinical Site Disease Group Leader, Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, Miami, FL, USA
#783 Phase II Trial of Loncastuximab Tesirine (WM-NET1 Trial) in Patients with Relapsed/Refractory and High-Risk Waldenström Macroglobulinemia
Monday, December 14, 2026

11:00 – 11:15 AM CT

Location: New Orleans Theatre B

Shayna Sarosiek, MD, Bing Center for Waldenström Macroglobulinemia, Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA

#784
Fixed-Duration Loncastuximab Tesirine Induces a High Rate of Complete and Durable Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma – Report of a Multicenter Phase II Study

Monday, December 14, 2026

11:15 – 11:30 a.m. CT

Location: New Orleans Theatre B

Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, Miami, FL, USA
#920
Results From the Phase 3 LOTIS-5 Study: Efficacy and Safety of Loncastuximab Tesirine plus Rituximab vs Immunochemotherapy (R-GemOx) in Patients with Relapsed or Refractory DLBCL

Monday, December 14, 2026

3:00 – 3:15 p.m. CT

Location: New Orleans Theatre A

Mehdi Hamadani, MD, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

Conference Call Information

To access today’s conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ZYNLONTA

ZYNLONTA is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com.

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

(Press release, ADC Therapeutics, NOV 4, 2026, View Source [SID1234674156])

Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing

On November 4, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, reported that, its wholly-owned subsidiary, Skinject, Inc. ("SkinJect"), has entered into a non-binding letter of intent ("LOI") with an undisclosed special purpose acquisition company ("SPAC") for a proposed business combination involving SkinJect ("Business Combination"). The LOI contemplates a $135 million pre-money enterprise valuation for SkinJect and concurrent equity financing to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential New Drug Application ("NDA").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proposed transaction is intended to establish a separately listed company dedicated to SkinJect, with Medicus seeking to retain majority economic and voting ownership. This structure would provide a dedicated financing platform for SkinJect’s rare-disease dermatology program while preserving Medicus shareholders’ participation in its potential future value.

"We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders," said Dr. Raza Bokhari, Medicus Exec. Chairman and CEO. "The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth".

Proposed Transaction and Financing

Under the proposed terms, the SPAC would acquire 100% of SkinJect in exchange for newly issued common shares of the combined company. Final ownership would depend on the agreed capitalization, including retained SPAC cash, public and sponsor shares, warrants and other potentially dilutive securities, to be negotiated in the definitive agreement.

Non-binding Status and Closing Conditions

The LOI outlines proposed transaction terms, including the contemplated valuation, financing, ownership and closing conditions. Except for certain limited procedural provisions, the proposed transaction terms are non-binding. Completion of the proposed transaction would be subject to satisfactory due diligence, negotiation and execution of definitive agreements, completion of the financing, satisfaction of the minimum-cash condition, required board and shareholder approvals, applicable SEC filings and registration requirements, stock exchange listing approval and other agreed closing conditions. There can be no assurance that definitive agreements will be signed, that the financing will be secured or that the transaction will be completed. The Company currently anticipates completing the proposed business combination during the first half of 2027; however, there can be no assurance that the transaction will close within this anticipated timeframe or at all.

SkinJect Development in Gorlin Syndrome

SkinJect is an investigational dissolvable microneedle-array patch designed to deliver doxorubicin directly into basal cell carcinoma lesions. Medicus has focused future internally sponsored SkinJect clinical development on Gorlin syndrome, a rare genetic condition associated with multiple, recurrent basal cell carcinomas. The FDA has issued a "Study May Proceed" letter authorizing initiation of SKNJCT-005, the Company’s planned NDA-enabling registrational Phase 2b study. SkinJect remains investigational, and any NDA submission or approval would depend on clinical results and applicable regulatory requirements.

(Press release, Medicus Pharma, NOV 4, 2026, View Source [SID1234674172])